Remdesivir | CAS:1809249-37-3

We serve Remdesivir CAS:1809249-37-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Remdesivir

Product Name: Remdesivir
Synonym: Remdesivir; GS-5734; GS 5734; GS5734, Prodrug of GS-441524; Prodrug of GS441524; Prodrug of GS441524;
CAS#: 1809249-37-3 
Chemical Formula: C28H36N5O8P 
Exact Mass: 601.2301 
Molecular Weight: 601.5968 
IUPAC/Chemical Name: 2-ethylbutyl ((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[1,2-b]pyridazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate

Also, we are offering steps of Remdesivir intermediates:
CAS:1355357-49-1
CAS:1911578-98-7
CAS:1355049-92-1
CAS:1191237-69-0
CAS:1191237-80-5
 
Application:
Remdesivir has been found to show reasonable antiviral activity against more distantly related viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus, and MERS-coronavirus and Coronavirus. GS-5734 was rapidly pushed through clinical trials due to the 2013–2016 West African Ebola virus epidemic crisis.
 
Gilead Sciences has recently confirmed that it is demonstrating whether the experimental Ebola drug Remdesivir may cause a fight against a new coronavirus (2019-nCoV) emerging in China. The company said that "active discussions are underway with researchers and clinicians in the United States and China about the potential use of Remdesivir in therapy."
Remdesivir, also known as GS-5734, is an experimental RNA polymerase inhibitor developed by Gilead Sciences in 2014 in collaboration with the Centers for Disease Control and Prevention (CDC) and the U.S. Army Medical Institute for Infectious Diseases Anthony Fossie, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH), stated in a comment on JAMA Network that SARS-CoV and MERS-CoV are being used as prototypes to develop treatment strategies for 2019-nCoV. "Broad-spectrum antivirals, such as Remdesivir, lopinavir / ritonavir and interferon, have shown promise against MERS-CoV in animal models and are evaluating their activity against 2019-nCoV," he said.



Contact us for information like Remdesivir chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Remdesivir APIs physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Remdesivir APIs Use and application,Remdesivir technical grade,usp/ep/jp grade.


Related News: The WHO says humans are mostly infected with MERS through direct or indirect contact with infected dromedary camels, and human-to-human transmission is rare.4-[(6-oxo-1H-pyrimidin-2-yl)amino]benzonitrile manufacturer In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired.Calcium beta-hydroxy-beta-methylbutyrate supplier Travel alerts: As the Wuhan coronavirus spreads around China, infecting more people, a number of countries have raised their travel advisory warnings.4-(dibiphenyl-4-ylamino)phenylboronic acid vendor These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation? whose founders — in addition to Ed Damiano — include other parents of children with type 1 diabetes and people with type 1 diabetes. Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible.Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships.